CME Oncoplastic Surgery Course
Targeted Medical Education (TME) Foundation's first CME Oncoplastic Surgery Course Co-directed by Barry Rosen, MD and Anne Peled, MD June 28–29, 2019 Hyatt Cent...
FEATURED, News, Industry, Oncoplastic, Surgery
GROUNDHOG DAY: Silicone implant complications revisited
ANALYSIS OF 100,000 PATIENTS SHOWS SILICONE IMPLANTS ASSOCIATED WITH CERTAIN SYSTEMIC DISEASES Do you remember when the FDA lifted a 14-year ban on silicone imp...
FEATURED, News, Genetic Testing, Genetics, BRCA
DIRECT TO CONSUMER GENE TESTING MAY BE A GAME CHANGER
What are your plans for patients who arrive with their genetic profiles? On March 16, 2018, the United States Food and Drug Administration (FDA) authorized 23an...
Genetic Testing, Genetics, Research, News, FEATURED
Obsolete Guidelines for Genetic Testing Miss Breast Cancer Patients Who Could Benefit
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? Approximately 330,000 patients are diagnosed with breast cance...
FEATURED, News, Genomics, Radiation, Risk Assessment, Regional Management
Influence of the subtype on local recurrence risk of breast cancer with or without radiotherapy
Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence Studies have shown that certain intrinsic subtypes of breast cancer are associate...
FEATURED, News, Genomics, Risk Assessment, Histology
Standard Light Microscopy Illuminates a Molecular Mystery
Why do triple negative breast cancers in BRCA-1 patients have a better prognosis?
FEATURED, News, Genetics, Genetic Testing, Risk Assessment
Genome-wide Association Studies (GWAS) may be future for helping determine relative risk
Genetics have a thumb on the scale for just about every human trait Francis Collins, current Director of the NIH and member of the Human Genome Project, predic...
Neoadjuvant Treatment, BRCA, PARP Inhibitors, FEATURED, News
Neoadjuvant Single-Agent PARP Inhibitor Appears Promising in BRCA Patients
BRCA patients may be able to take only one pill a day in a neoadjuvant setting The results of a small phase II trial suggest that the PARP inhibitor, talazopari...
Risk Factors Identified for Recurrence after NeoAdjuvant Therapy
Simple clinical score assists decision-making following neoadjuvant therapy There is an increased use of neoadjuvant therapy (NAC) despite a lack of survival be...
